FDA accepts Merck supplemental BLAs to update Keytruda dosing frequency

The FDA accepts for review six supplemental marketing applications from Merck (NYSE:MRK) to update the dosing frequency for Keytruda (pembrolizumab) to include a 400 mg dose infused over 30 minutes once every six weeks, double the time of the currently approved regimen.

The agency’s action date is February 18, 2020.

https://seekingalpha.com/news/3476401-fda-accepts-supplemental-blas-merck-update-dosing-frequency-keytruda